Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer
16 oct. 2017 08h00 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
06 sept. 2017 07h00 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference
31 août 2017 16h05 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
09 août 2017 16h01 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Announces Leadership Change
20 juil. 2017 16h01 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, July 20, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
10 juil. 2017 16h01 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, July 10, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Prices Public Offering of Common Stock
06 juin 2017 09h20 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, June 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
05 juin 2017 16h01 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, June 05, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
23 mai 2017 08h00 HE
|
Aeglea BioTherapeutics
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business...
Aeglea BioTherapeutics to Present at the UBS 2017 Global Healthcare Conference
16 mai 2017 16h01 HE
|
Aeglea BioTherapeutics
AUSTIN, Texas, May 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...